Abstract
The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
Original language | English (US) |
---|---|
Pages (from-to) | 43-56 |
Number of pages | 14 |
Journal | Therapeutic Advances in Respiratory Disease |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Feb 1 2016 |
Keywords
- combined inhaler
- fluticasone furoate/vilanterol trifenatate
- inhaled corticosteroid
- long-acting β2 agonist
- persistent asthma
- powder inhaler
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology (medical)